-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
0 1
1.
640.
2, and named IHU
.
The virus has attracted widespread attention because the virus contains 46 mutation points and 37 deletions that affect the spike protein, suggesting that it may have a strong immune evasion ability
Research results (Source: Medrxiv ) Medrxiv Epidemiologist Eric Feigl-Ding tweeted (Source: Twitter)
The World Health Organization classifies new coronavirus variants into Variants of Concern (VOC) and Specific Variants of Interest (VOI) according to their transmission and pathogenicity.
Publication of Latin naming conventions for 5 VOCs and 6 VOIs .
For the correlation of new coronavirus variants, Nextstrain Clades gave an overall relationship diagram .
Table 1 Summary of names of new coronavirus variantsData source: Reference [1]; Tabulation: Biodiscovery editorial team
The vaccine development process typically has five stages .
In the first stage, the design, proof of concept and preclinical testing of the vaccine will be carried out, and the sample vaccine will be tested on animals for safety and effectiveness; the second to fourth stages will enter the clinical trial stage, and the vaccine will be obtained by gradually expanding the scale of the test.
Safety and efficacy data in people with different signs; the fifth stage is the post-market surveillance stage.
Comparative analysis of main technical routes of new crown vaccine research and developmentComparative analysis of main technical routes of new crown vaccine research and development
WHO Director-General Tedros Adhanom Ghebreyesus said that to achieve the goal of vaccinating 70% of the world's population, the world needs 11 billion doses of vaccines .
The strong demand for vaccines in the international community has stimulated the production efficiency of vaccine manufacturers in various countries .
UK-based AstraZeneca has a production capacity of 3 billion doses in 2021 .
Pfizer in the United States has a production capacity of 2 billion doses in 2021, and is expected to reach 3 billion doses in 2022; Novavax has a production capacity of 2 billion doses .
China's Sinopharm's vaccine production capacity will reach 3 billion doses in 2021, while Sinovac's production capacity will also reach 2 billion doses per year .
WHO Director-General Tedros Adhanom Ghebreyesus said that to achieve the goal of vaccinating 70% of the world's population, the world needs 11 billion doses of vaccines .
Design capacity of major overseas COVID-19 vaccine manufacturers (100 million doses/year) (Source: CITIC Construction Investment) The clinical trial progress and design capacity (dose/year) of major domestic manufacturers of new crown vaccines (Source: CITIC Construction Investment) In terms of international market share, foreign vaccine manufacturers account for about 76%, and domestic manufacturers account for about 9%, of which Oxford University/Azerbaijan STRIKEN, Pfizer, Johnson & Johnson, and Moderna each account for 31%, 20%, 14%, and 10% of the market share .
China's Kexing Bio, Sinopharm, and CanSino accounted for 6.
2%, 1.
9% and 0.
94% respectively .
Orders of global new crown vaccine companies (million doses) (Source: CITIC Construction Investment) 04 " Frequent virus iterations, vaccine efficacy to be evaluated" " Vaccine iterations to be frequent, vaccine efficacy to be assessed " The experience of many times in the history of infectious disease prevention and control shows that establishing an immune barrier through vaccination to protect susceptible people and reduce the possibility of virus mutation during transmission is the most effective prevention and control measure .
Since 2021, mutant viruses that spread faster and are more virulent have appeared in some parts of the world, and the development cycle of vaccines is mostly six months to several years.
Vaccines developed with the classic strain model may have reduced protection against mutant strains.
, does not rule out breaking through the defenses of existing vaccines .
With the entire population vaccinated, Israel has suddenly seen a large number of new infections, most of which are in the vaccinated population infected with the delta virus .
The World Health Organization said that the mutation of the virus is unlikely to make the vaccine completely ineffective, and the vaccine is still effective in preventing severe disease and reducing death.
The new crown vaccine that has been approved can cause a broad immune response, and can provide at least some degree of protection against the mutated virus .
End Reference: [1] World Health Organization.
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] https:// activities/tracking-SARS-CoV-2-variants/.
[1] World Health Organization.
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] World Health Organization .
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] https:// variants/.
This article is an original biological exploration, and personal forwarding and sharing are welcome
.
If any other media or website needs to be reprinted, the source Biological Discovery must be indicated before the text
.
leave a message here
" New coronavirus variants do not necessarily bring high risk "
" New coronavirus variants do not necessarily bring high risks " " New coronavirus variants do not necessarily bring high risks " "New coronavirus variants do not necessarily bring high risks"Recently, a new variant of the new coronavirus was reported in France, numbered B.
1.
640.
2, and named IHU
.
The virus has attracted widespread attention because the virus contains 46 mutation points and 37 deletions that affect the spike protein, suggesting that it may have a strong immune evasion ability
Research results (Source: Medrxiv ) Medrxiv Epidemiologist Eric Feigl-Ding tweeted (Source: Twitter)
The proportion of some countries infected with the new coronavirus variant (Source: Our World in Data) Since the outbreak of the new coronary pneumonia epidemic, it has continuously evolved and mutated, and a variety of mutant strains have been produced one after another .
The World Health Organization classifies new coronavirus variants into Variants of Concern (VOC) and Specific Variants of Interest (VOI) according to their transmission and pathogenicity.
Publication of Latin naming conventions for 5 VOCs and 6 VOIs .
For the correlation of new coronavirus variants, Nextstrain Clades gave an overall relationship diagram .
Table 1 Summary of names of new coronavirus variantsData source: Reference [1]; Tabulation: Biodiscovery editorial team
Association of new coronavirus variants (Source: Covariants) Report of COVID -19 cases per 100,000 population by country and region from December 20 to 26, 2021 ( Source : WHO official website ) Multi-country research and development of vaccines, rapid global launch " The new crown epidemic has detonated a global public health crisis, and countries with research and development conditions have started vaccine research and development at the beginning of the outbreak of the new crown epidemic .
The vaccine development process typically has five stages .
In the first stage, the design, proof of concept and preclinical testing of the vaccine will be carried out, and the sample vaccine will be tested on animals for safety and effectiveness; the second to fourth stages will enter the clinical trial stage, and the vaccine will be obtained by gradually expanding the scale of the test.
Safety and efficacy data in people with different signs; the fifth stage is the post-market surveillance stage.
Comparative analysis of main technical routes of new crown vaccine research and developmentComparative analysis of main technical routes of new crown vaccine research and development
The world's leading clinical research on COVID-19 vaccine (data source: WHO, collated by CITIC Construction Investment)
The results of the third phase of the global COVID-19 vaccine trial (source: CSC)Table 2Basic information of 20 vaccines approved for use in at least one country in the world Table 2 Basic information of 20 vaccines approved for use in at least one country in the world 20 vaccines in the world Basic information on vaccines approved for use in at least one country
Data sources: Vaccine Tracker; Tabulation: BioQuest editorial team
Data source: Vaccine Tracker; Tabulation: Bio-Exploration Editing Team Tabulation: Bio-Exploration Editing Team 03 " R&D and production in line with expectations, Chinese and American companies lead the industry " " R&D and production in line with expectations, Chinese and American companies lead the industry " " R&D and production in line with expectations , Chinese and American companies lead the industry ” Worldwide, the development and distribution of vaccines and the speed of virus spread and mutation determine the duration of the new coronary pneumonia .WHO Director-General Tedros Adhanom Ghebreyesus said that to achieve the goal of vaccinating 70% of the world's population, the world needs 11 billion doses of vaccines .
The strong demand for vaccines in the international community has stimulated the production efficiency of vaccine manufacturers in various countries .
UK-based AstraZeneca has a production capacity of 3 billion doses in 2021 .
Pfizer in the United States has a production capacity of 2 billion doses in 2021, and is expected to reach 3 billion doses in 2022; Novavax has a production capacity of 2 billion doses .
China's Sinopharm's vaccine production capacity will reach 3 billion doses in 2021, while Sinovac's production capacity will also reach 2 billion doses per year .
WHO Director-General Tedros Adhanom Ghebreyesus said that to achieve the goal of vaccinating 70% of the world's population, the world needs 11 billion doses of vaccines .
Design capacity of major overseas COVID-19 vaccine manufacturers (100 million doses/year) (Source: CITIC Construction Investment) The clinical trial progress and design capacity (dose/year) of major domestic manufacturers of new crown vaccines (Source: CITIC Construction Investment) In terms of international market share, foreign vaccine manufacturers account for about 76%, and domestic manufacturers account for about 9%, of which Oxford University/Azerbaijan STRIKEN, Pfizer, Johnson & Johnson, and Moderna each account for 31%, 20%, 14%, and 10% of the market share .
China's Kexing Bio, Sinopharm, and CanSino accounted for 6.
2%, 1.
9% and 0.
94% respectively .
Orders of global new crown vaccine companies (million doses) (Source: CITIC Construction Investment) 04 " Frequent virus iterations, vaccine efficacy to be evaluated" " Vaccine iterations to be frequent, vaccine efficacy to be assessed " The experience of many times in the history of infectious disease prevention and control shows that establishing an immune barrier through vaccination to protect susceptible people and reduce the possibility of virus mutation during transmission is the most effective prevention and control measure .
Since 2021, mutant viruses that spread faster and are more virulent have appeared in some parts of the world, and the development cycle of vaccines is mostly six months to several years.
Vaccines developed with the classic strain model may have reduced protection against mutant strains.
, does not rule out breaking through the defenses of existing vaccines .
With the entire population vaccinated, Israel has suddenly seen a large number of new infections, most of which are in the vaccinated population infected with the delta virus .
The World Health Organization said that the mutation of the virus is unlikely to make the vaccine completely ineffective, and the vaccine is still effective in preventing severe disease and reducing death.
The new crown vaccine that has been approved can cause a broad immune response, and can provide at least some degree of protection against the mutated virus .
End Reference: [1] World Health Organization.
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] https:// activities/tracking-SARS-CoV-2-variants/.
[1] World Health Organization.
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] World Health Organization .
Tracking SARS-CoV-2 variants [EB/OL].
(2021-08-09) [2021-08-09] https:// variants/.
This article is an original biological exploration, and personal forwarding and sharing are welcome
.
If any other media or website needs to be reprinted, the source Biological Discovery must be indicated before the text
.
leave a message here
